SAB Biotherapeutics CMO Alexandra Kropotova Withholds 988 Shares for Taxes

What Happened
Alexandra Kropotova, Chief Medical Officer of SAB Biotherapeutics (SABS), had 988 shares of common stock withheld to satisfy tax withholding obligations upon the vesting of restricted stock units (RSUs). The transaction is reported as code F (tax withholding/payment of exercise price) and shows no per-share price or cash value (N/A).

Key Details

• Transaction date: 2026-06-25; Form 4 filed: 2026-06-26.
• Transaction type/code: F — shares withheld to satisfy tax withholding on vested RSUs.
• Shares withheld: 988 shares; price and total value: N/A (net share settlement for taxes).
• Reported ownership per filing: includes 37,158 shares of common stock and 5,150 RSU-related shares that remain subject to vesting.
• Footnotes: F1 = shares withheld to satisfy tax withholding on RSU vesting; F2 = breakdown of current and unvested RSU shares; F3 = each RSU equals one share.
• Filing appears timely (filed one day after the transaction).

Context
This is a routine net share settlement to cover tax obligations upon RSU vesting (not a market sale or new purchase). Such withholdings reduce the number of shares delivered to the insider and do not necessarily indicate a change in the insider’s view of the company.